YourBio Health

What YourBio Health does

YourBio Health is a Medford, Massachusetts-based medical device company that develops and commercializes the TAP (Touch-Activated Phlebotomy) family of virtually painless blood collection devices, built on its proprietary HALO (HAllow Optic) bladeless microneedle array technology. Founded in 2011 by Flagship Pioneering (originally as Seventh Sense Biosystems, rebranded in August 2021), the company targets three primary use cases: decentralized clinical trials for biopharmaceutical sponsors, fertility and frequent-monitoring applications in healthcare provider settings, and OEM-embedded consumer wellness and diagnostic products. Its product portfolio includes TAP II (CE Marked, 2021), TAP Micro Select (FDA 510(k) cleared April 2023 and CE Marked October 2023, collecting up to 500µL of capillary whole blood), and supporting services.

The company operates a hybrid go-to-market combining direct-to-consumer device sales through its website, an OEM/embedded licensing model (flagship partner Myriad Genetics has consumed over 500,000 TAP devices supporting 1M+ SneakPeek tests since 2021), and enterprise sales to clinical trial sponsors, academic medical centers (Columbia University Fertility Center, Massachusetts General Hospital, Boston Children's Hospital), and substance-use monitoring and pediatric research partners (RecoveryTrek, O'Ryan.Health). Revenue streams are hardware sales, technology licensing/royalties, and clinical trial services. Pricing for individual consumer tests has been disclosed at £99.99 for the UK COVID-19 antibody service, but broader device and licensing pricing is not publicly disclosed.

YourBio Health raised over $80 million in cumulative funding, led by Flagship Pioneering with participation from Newpath Partners, LabCorp, Novartis, Polaris Partners, and the Bill & Melinda Gates Foundation. In December 2025, Hims & Hers Health announced a definitive agreement to acquire YourBio Health to bring TAP/HALO blood sampling in-house for its consumer diagnostics platform; the deal is reported as expected to close in early 2026, with one source indicating completion on February 24, 2026.

Name

YourBio Health

Legal name

YourBio Health, Inc.

Website

https://yourbiohealth.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

11–50 employees

Short description

YourBio Health is a Medford, MA-based medical device company that develops the TAP family of virtually painless blood collection devices using proprietary HALO bladeless microneedle technology, serving clinical trial sponsors, healthcare providers, and OEM partners such as Myriad Genetics' SneakPeek. Acquired by Hims & Hers Health in late 2025.

Ownership category

akta.pro rank

Product category

Medical Devices - Blood Collection

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD)

akta.pro secondary industries

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG), Clinical Trial Sample Collection & Site Phlebotomy Services (HLAGACAJ)

Keywords

• Blood collection devices
• Microneedle blood sampling
• Capillary blood collection
• Diagnostic medical devices
• At-home blood testing

Headquarters

HQ city

Medford

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. TAP Device Sales: YourBio Health sells its TAP blood collection devices directly to consumers through its website and to partner companies who embed the technology into their products. The company also supplies devices for clinical trials, diagnostic applications, and wellness testing services.
2. Technology Licensing: YourBio Health licenses its patented TAP and HALO technologies to other companies for use in their products. Examples include partnerships with Myriad Genetics for SneakPeek tests, Gateway Genomics, and O'Ryan.Health for pediatric studies.
3. Clinical Trial Services: YourBio provides devices and services customized for clinical trials, including sample tracking services. Partnered with biopharmaceutical companies and academic research hospitals for decentralized clinical trials.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

YourBio Health manufactures and commercializes the TAP (Touch-Activated Phlebotomy) family of blood collection devices built on proprietary HALO bladeless microneedle array technology. The devices enable virtually painless capillary blood collection from the upper arm in approximately 2-3 minutes, producing up to 500µL of high-quality samples compatible with standard laboratory workflows. Products include TAP II (CE Marked) and TAP Micro Select (FDA 510(k) cleared and CE Marked), sold to healthcare providers, biopharmaceutical clinical trial sponsors, OEM partners, and directly to consumers for at-home testing.

Product overview

YourBio Health is a medical device company offering the TAP (Touch-Activated Phlebotomy) family of blood collection devices, the world's first push-button blood collection technology using proprietary HALO bladeless microneedle arrays. The product portfolio includes TAP II (CE marked for Europe), TAP Micro Select (FDA 510(k) cleared and CE marked), and associated sampling services. The technology enables virtually painless capillary blood collection from the upper arm, replacing traditional phlebotomy and fingerstick methods for clinical trials, diagnostic testing, and wellness applications. The company provides complementary services including sample tracking and partners with diagnostic companies, clinical trial operators, and healthcare providers. In December 2025, Hims & Hers Health announced acquisition of YourBio Health, expected to close in early 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• TAP Device with HALO Technology Push-button blood collection device using proprietary bladeless microneedle array technology that enables virtually painless capillary blood collection from the upper arm in approximately 2-3 minutes. FDA 510(k) cleared for clinical blood collection.
• TAP II Second-generation blood collection device with CE Mark for European markets. Features standardized detachable serum and plasma collection containers that fit into standard laboratory workflows, with expanded blood volume collection capability compared to first generation.
• TAP Micro Select FDA 510(k) cleared and CE Marked blood collection device using HALO technology. Delivers virtually painless, large-volume collection of up to 500µL of whole capillary blood. Designed for decentralized clinical trials and health/wellness testing applications.
• COVID-19 Antibody Test (UK) Nearly painless at-home COVID-19 antibody test service offered to UK consumers using TAP device technology. Provides quantitative antibody level information with results delivered online within 24 hours of sample receipt at the lab.

Quantifiable outcome

• Over 80% of patients chose TAP device over venipuncture and 75% over fingerstick in clinical studies
• +5 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, key and minor.

• Hims & Hers HealthcoreStrategic or Co-development Partner · 3 December 2025Hims & Hers Health announced definitive agreement to acquire YourBio Health in December 2025, expected to close in early 2026. The acquisition brings patented pain-free blood sampling technology in-house to enhance Hims & Hers' blood collection capabilities through integration of the TAP device built on HALO technology.
• O'Ryan.HealthkeyStrategic or Co-development Partner · 31 July 2024Partnership to provide TAP capillary blood sampling devices for O'Ryan.Health's pioneering parent-led pediatric studies including 'The Healthy Kids Study' and 'The JDM Study' for Juvenile Dermatomyositis research.
• RecoveryTrekkeyStrategic or Co-development Partner · 16 July 2024Partnership to provide phosphatidylethanol (PEth) alcohol biomarker testing using TAP Micro Select device through RecoveryTrek's PROOF virtual remote collection platform for substance use disorder patients and professional monitoring programs.
• Myriad Genetics (SneakPeek)coreOEM/ Whitelabel/ Licensing Partner · 2 May 2024YourBio provides TAP technology for Myriad Genetics' SneakPeek Early Gender DNA Test. Since 2021, YourBio contributed over half a million TAP technology products supporting over 1 million SneakPeek test sales. TAP devices provide virtually painless sampling for customers.
• Boston Children's HospitalkeyStrategic or Co-development Partner · 1 January 2024Clinical study partnership where patients and parents chose TAP Device with HALO Technology over venipuncture and lancet 80% of the time due to ease and comfort.
• Columbia University Fertility CenterkeyStrategic or Co-development Partner · 23 October 2023YourBio provides TAP devices to Columbia University Fertility Center to take pain and stress out of frequent blood draws necessary for IVF treatment. Dr. Zev Williams noted clear opportunity to make fertility journey more tolerable for patients.
• Moderna and Evidation HealthkeyStrategic or Co-development Partner · 4 August 2022YourBio enabled blood collection for Moderna's COVID-19 antibody response study during Omicron wave using TAP II device. The completely decentralized clinical trial approach 'sets a precedent for greater research access' according to company leadership.
• Gateway GenomicskeyOEM/ Whitelabel/ Licensing Partner · 29 June 2021Gateway Genomics leverages YourBio's TAP II technology in SneakPeek Snap for at-home blood collection. Study published in International Journal of Pregnancy & Child Birth showed 90% of participants found SneakPeek Snap painless vs 22% for lancet.
• HumanPeopleminorOEM/ Whitelabel/ Licensing Partner · 5 March 2021UK-based personalized health company integrating TAP II for home collection of blood samples. HumanPeople reported 100% success in tests after switching from finger prick tests due to high failure rates.
• Affinity Biomarker LabskeyStrategic or Co-development Partner · 2 February 2021Affinity Biomarker Labs provides direct-to-patient testing and lab services for consumer healthcare companies using TAP II devices. Praised ease, comfort, and convenience of TAP II for patient blood collection without leaving home.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Spot On Sciences: Spot On Sciences developed HemaSpot, a dried blood spot collection device used for at-home sample collection in clinical trials and population health studies. It is a direct competitor in the remote blood sampling category overlapping with YourBio's clinical trial and consumer testing applications.
• Capitainer: Capitainer is a Swedish developer of qDBS dried blood spot sampling devices for at-home blood collection. It serves clinical research, therapeutic drug monitoring, and population health, competing directly with YourBio for decentralized trial and remote patient sampling contracts.
• Tasso: Tasso is a direct competitor offering at-home capillary blood collection devices using microneedle technology for clinical research, decentralized trials, and patient-centric sampling. Both companies target the same decentralized clinical trial and consumer diagnostics use cases with virtually painless blood draw alternatives to venipuncture.
• Trajan Scientific and Medical (Neoteryx): Trajan Scientific acquired Neoteryx, maker of Mitra microsampling devices that enable volumetric dried blood spot collection at home. Mitra is a competing remote/microsampling solution used in clinical trials and at-home testing, comparable in end-use and customer base to YourBio's TAP products.

Broad incumbents

• Laboratory Corporation of America (LabCorp): LabCorp is a major clinical laboratory network that processes diagnostic blood samples and was also a past investor in Seventh Sense Biosystems / YourBio Health. It sits at the downstream lab services layer of the value chain that YourBio's TAP devices feed into.
• Becton Dickinson: Becton Dickinson is the dominant incumbent in blood collection devices, including capillary and venous sampling systems used in hospitals, labs, and clinical trials. YourBio's Chief Growth Officer Thomas Briggs previously led BD's Emerging Specimen Management Business, underscoring the strategic overlap and BD's role as a broad competitor in the specimen collection space.
• Sarstedt: Sarstedt is a major manufacturer of blood collection systems, capillary sampling devices, and laboratory consumables. As a broad incumbent with established distribution in hospitals and labs, it represents a conventional incumbent alternative to YourBio's decentralized TAP solution.
• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies, processing blood samples for diagnostic testing. While it does not manufacture collection devices, its lab services are the downstream destination for YourBio's TAP-collected samples, making it an adjacent incumbent in the value chain.
• Greiner Bio-One: Greiner Bio-One manufactures blood collection tubes and vacuum-based phlebotomy systems widely used in clinical laboratories and diagnostics. As a broad incumbent in the specimen collection category, it competes with YourBio for hospital and diagnostic lab relationships.

Emerging players

• Babson Diagnostics: Babson Diagnostics is developing fingertip blood collection and analytics for routine diagnostic testing at retail pharmacy locations. It overlaps with YourBio in the at-home and pharmacy-based diagnostic testing space, though it focuses on retail pharmacy channels rather than direct-to-consumer and clinical trials.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/yourbio_health
• Facebookfacebook.com/YourBioHealth
• LinkedInlinkedin.com/company/yourbio-health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds18 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YourBio Health